Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

by Michael A. Nauck, David A. D‘Alessio
Published 2022-09-01

Pharmacological antagonism of the incretin system protects against diet-induced obesity

by Berit Svendsen, Megan E. Capozzi, Jingjing Nui, Sarah A. Hannou, Brian Finan, Jacqueline Naylor, Peter Ravn, David A. D'Alessio, Jonathan E. Campbell
Published 2020-02-01

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

by Stephen J. Nicholls, Santiago Tofé, Carel W. le Roux, David A. D’Alessio, Russell J. Wiese, Imre Pavo, Katelyn Brown, Govinda J. Weerakkody, Meltem Zeytinoglu, Irene C. Romera
Published 2024-02-01

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

by Tamer Coskun, Kyle W. Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B. Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Uma Kuchibhotla, Julie S. Moyers, Charles T. Benson, Ruth E. Gimeno, David A. D'Alessio, Axel Haupt
Published 2018-12-01

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

by Francis S. Willard, Jonathan D. Douros, Maria B.N. Gabe, Aaron D. Showalter, David B. Wainscott, Todd M. Suter, Megan E. Capozzi, Wijnand J.C. van der Velden, Cynthia Stutsman, Guemalli R. Cardona, Shweta Urva, Paul J. Emmerson, Jens J. Holst, David A. D’Alessio, Matthew P. Coghlan, Mette M. Rosenkilde, Jonathan E. Campbell, Kyle W. Sloop
Published 2020-09-01